Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 13/20 | 0.46 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23828239 | 0.73 | CFTR (0.67) | CFTR | |
| SCHEMBL23828237 | 0.67 | CFTR (0.52) | CFTRHTR2A | |
| SCHEMBL31020987 | 0.66 | CFTR (0.70) | CFTR | |
| SCHEMBL23828257 | 0.66 | CFTR (0.78) | CFTRMAPT | |
| SCHEMBL31020947 | 0.66 | CFTR (0.78) | CFTRMAPT | |
| SCHEMBL29910393 | 0.64 | PLA2G1B (0.43) | CFTRHTR2AKDM5A | |
| SCHEMBL23828253 | 0.63 | CFTR (1.00) | CFTR | |
| SCHEMBL21787536 | 0.61 | HTR2A (0.57) | CFTRHTR2AKDM5AHRH4 | |
| SCHEMBL17546291 | 0.59 | HTR2A (0.52) | HTR2AKDM5A | |
| SCHEMBL23828291 | 0.59 | CFTR (0.79) | CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3820867-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2023-09-13 | — | — | EP | claimed |
| US-20210292324-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2021-09-23 | — | — | US | claimed |
| EP-3820867-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2023-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292324-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC5 | CFTR 1/4885NAMPT 2770/4885MAPT 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.